Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

STRICT

Financiado

Cerrado

SN The first blood biomarker to accurately STratify mortality Risk In patients...

SN The first blood biomarker to accurately STratify mortality Risk In patients with Cardiac arrhyTmia Cardiovascular disease (CVD) is the no. 1 killer worldwide. 25% of all CVD mortality is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate... ver más

14/12/2020

Innovasjon Norge

120K€

Presupuesto del proyecto: 120K€

Líder del proyecto

Innovasjon Norge No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-12-14

INNOSUP-02-2019-2020: European SME innovation Associate -...

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

Innovasjon Norge

119.81K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2015-3515-1 ADAS - CARACTERIZACIÓN AUTOMÁTICA DEL SUSTRATO ARRÍTMICO Y E... 175K€ Cerrado

SN-marker Secretoneurin SN the first blood biomarker to accurately... 71K€ Cerrado

EU-CERT-ICD Comparative Effectiveness Research to Assess the Use of Prim... 8M€ Cerrado

USART Ultrasound guided cardiac arrythmia treatment 1M€ Cerrado

PROFID Implementation of personalised risk prediction and preventio... 23M€ Cerrado

DPI2015-70821-R CARACTERIZACION DE LA MIOCARDIOPATIA ARRITMOGENICA A PARTIR... 75K€ Cerrado

Duración del proyecto: 15 meses Fecha Inicio: 2019-09-11
Fecha Fin: 2020-12-14

Líder del proyecto

Innovasjon Norge No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 120K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cardiovascular disease (CVD) is the no. 1 killer worldwide. 25% of all CVD mortality is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate decision-making and patient survival. To assess the patient’s status, cardiologists currently ask: physical exams, some cardiac biomarkers data, an ECG (which may detect an arrythmia) and an echocardiogram to measure the blood ejection from the left ventricle (LVEF), since there is a correlation between LVEF and risk of ventricular arrhythmias. If LVEF is < 35%, the patient is eligible for implantable cardioverter-defibrillator (ICD) surgery, which costs at least 20K€. Still, around 51 % of victims of SCD have normal LVEF. In addition, 67% of all implemented ICDs are never activated because those patients were (unknowingly) at low-risk for arrhythmias, which represents a 1.3B€ overtreatment cost / year in the EU alone. CardiNor is bringing to market a new in vitro diagnostic (IVD) test to measure blood levels of Secretoneurin (SN), a globally patented biomarker and the only one shown to be specifically linked to ventricular arrhythmias. With SN data, cardiologists will be able to stratify patients according to their risk as well as to pinpoint high-risk patients not identified by the current diagnostic regime, thus reducing health burden costs and saving lives. CardiNor needs the SME Innovation Associate Programme to boost R&D activities within test maturation and effectively take it to TRL8. Currently, we do not have in-house expertise in biomedical device development or quality assurance. Therefore, we are looking to recruit an Innovation Associate. Acquiring these skills is important for CardiNor to maintain competitive advantage over coming years, positioning our company to high growth in the global CVD biomarkers market.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores